Nasdaq

FDA Approves Omeros’ YARTEMLEA® – First and Only Therapy Indicated for TA-TMA

SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA® (narsoplimab-wuug) for the treatment of ...
Business Wire

International Consortium of Complement Experts Receives €1.3 Million Grant to Study Role of MASP-2 and Lectin Pathway in Traumatic Brain Injury

“We believe that the lectin pathway plays a critical role in brain injury as evidenced by our published data showing that Omeros’ MASP-2 inhibitor OMS721 significantly reduced brain infarct size and ...
WebMD

FDA Approves Yartemlea, the First and Only Treatment for Transplant-Related Blood Vessel Damage

What Is Yartemlea, and Why Does It Matter? Yartemlea (narsoplimab-wuug) is a new medicine approved by the FDA for treating a rare and serious condition called transplant-associated thrombotic ...
BioWorld

IMG-025 ameliorates IgA nephropathy by inhibiting lectin-driven complement activation

Immunoglobulin A (IgA) nephropathy is the most prevalent glomerulonephritis worldwide that does not have a specific treatment. Its pathogenesis is complex and not well understood, but there is ...